Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic diseases, today announced that it has completed ...
The FDA approved an updated label for Vabysmo for the treatment of macular edema following retinal vein occlusion beyond 6 ...
The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated evidence supporting its continued efficacy and safety over longer treatment ...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...
Ollin Biosciences announces final data from randomized head-to-head study of OLN324 compared to faricimab in wAMD and diabetic macular edema: Austin, Texas Wednesday, April 1, 202 ...
MedPage Today on MSN
Red Meat Warning; 100 Meds With Supply Chain Risks; Jean Smart's Triple Bypass
Health news and commentary gathered by MedPage Today staff ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b ...
Merck initiates pivotal phase 2b/3 trial of Tiespectus, an investigational bispecific tie2 agonist/VEGF inhibitor, to treat neovascular age-related macular degeneration: Rahway, N ...
MK-8748 combines direct Tie2 pathway activation with VEGF inhibition, targeting persistent vascular leakage and vessel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results